Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02…
Month: September 2023
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02…
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of…
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of…
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table…
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table…
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia,…
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia,…
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — INmune Bio (NASDAQ: INMB), a clinical-stage…
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) — INmune Bio (NASDAQ: INMB), a clinical-stage…
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”),…
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”),…
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or…
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or…